Markets
Musk Protest
Protesters outside a New York City Tesla dealership on March 1 (Leonardo Munoz/Getty Images)

Palantir shareholders unsure if Musk’s attention is a good thing or not

The tech oligarch’s de facto takeover of the federal bureaucracy has huge implications for the company, whose biggest client remains the US government.

Matt Phillips

Elon Musk has been a fan of Palantir and its brash CEO for a while now. Over the weekend, he again demonstrated his support for Alex Karp after his new book topped The New York Times’ list of nonfiction bestsellers.

But not everyone seems comfortable with the level of attention the Tesla CEO is giving Palantir. While Musk’s Trump adjacency made Tesla one of the big winners of the market’s postelection run-up last year, his close association with right-wing politics both in the US and worldwide has had costs as well. Amid cratering sales in Europe, and signals that China sees Tesla as a potential point of leverage on the administration, Tesla stock has cratered by over 40% since December.

Over at a subreddit frequented by Palantir shareholders, Musk’s latest endorsement for Karp prompted a wave of debate both from those uncomfortable with his politics and work for the Trump administration ...

Comment
byu/Fun-Journalist2276 from discussion
inPLTR

... to those who see a closer association with Musk as a clear boon to Palantir...

Comment
byu/Fun-Journalist2276 from discussion
inPLTR

... and others who essentially say their investment in Palantir was premised in part on what they see as the potential corruption of the Trump administration and DOGE.

Comment
byu/Fun-Journalist2276 from discussion
inPLTR

Musk’s position as the Trump administration’s semiofficial deputy, tasked with cutting the federal workforce and taking unprecedented control of key parts of the US government’s tech infrastructure, could clearly be consequential for Palantir. The data analytics and AI software company’s main customer remains the US government, due to its long standing focus on defense and intelligence applications.

On Wall Street, analysts have been trying to game out how the Trump administration’s DC disruptions — including potentially unprecedented cuts to defense spending and Musk’s DOGE — will work out for contractors.

Wedbush analyst Dan Ives, a longtime Palantir bull, wrote in a note out Monday:

“Palantir is so well positioned for this new disciplined spending environment at the Pentagon and this will ultimately be a positive growth catalyst as the various programs are scrutinized and as Karp & Co. get a bigger seat at the table in the Beltway. We also believe Palantir is attached to many programs/contracts in the DOD that are safe and not at risk of getting cut in this new spending climate given their high priority.”

Likewise, BofA analysts suggested in a note that some software and IT services companies would benefit from the administration’s cuts to the federal workforce:

“We see the cohort as net beneficiaries in a market landscape measured by modernization, efficiency, and outsourcing. Booz Allen Hamilton (Booz Allen Hamilton) and Palantir (PLTR) are most strongly positioned to early DOGE actions, in our view.”

At any rate, both Tesla and Palantir are up on the day, after tumbling 20% and 30% over the last two weeks, suggesting that the “bro bubble” may have a bit of air left in it yet.

More Markets

See all Markets
markets

Spectrum owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its guidance for full-year revenue per user.

“It’ll be close either way in terms of whether we end up with net growth,” Fischer said.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets
Luke Kawa

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.